{"id":"https://openalex.org/W4362575132","doi":"https://doi.org/10.1016/j.reuma.2023.02.005","title":"Patient-reported outcomes in RA patients treated with tofacitinib or bDMARDs in real-life conditions in two Latin American countries","display_name":"Patient-reported outcomes in RA patients treated with tofacitinib or bDMARDs in real-life conditions in two Latin American countries","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4362575132","doi":"https://doi.org/10.1016/j.reuma.2023.02.005"},"language":"en","primary_location":{"id":"doi:10.1016/j.reuma.2023.02.005","doi":"https://doi.org/10.1016/j.reuma.2023.02.005","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.reuma.2023.02.005","pdf_url":null,"source":{"id":"https://openalex.org/S2756385725","display_name":"Reumatolog\u00eda Cl\u00ednica","issn_l":"1699-258X","issn":["1699-258X","1885-1398"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","poland-40","russia-white-list-4"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Reumatolog\u00eda Cl\u00ednica","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1016/j.reuma.2023.02.005","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5045599427","display_name":"Juan Manuel Reyes","orcid":"https://orcid.org/0000-0003-0806-7173","observed_orcids":["https://orcid.org/0000-0003-0806-7173"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"J.M. Reyes","raw_affiliation_strings":["Pfizer, Bogota, Colombia"],"raw_orcid":"https://orcid.org/0000-0003-0806-7173","affiliations":[{"raw_affiliation_string":"Pfizer, Bogota, Colombia","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019706772","display_name":"M.V. Gutierrez-Ardila","orcid":"https://orcid.org/0000-0001-6455-8685","observed_orcids":["https://orcid.org/0000-0001-6455-8685"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M.V. Gutierrez","raw_affiliation_strings":["Pfizer, Santiago, Chile"],"raw_orcid":"https://orcid.org/0000-0001-6455-8685","affiliations":[{"raw_affiliation_string":"Pfizer, Santiago, Chile","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083641788","display_name":"Hugo Madariaga","orcid":"https://orcid.org/0000-0001-5447-113X","observed_orcids":["https://orcid.org/0000-0001-5447-113X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. Madariaga","raw_affiliation_strings":["Centro Especializado de enfermedades neopl\u00e1sicas (CEEN), Arequipa, Peru"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centro Especializado de enfermedades neopl\u00e1sicas (CEEN), Arequipa, Peru","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075855325","display_name":"William Otero","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. Otero","raw_affiliation_strings":["Centro Servimed, Bucaramanga, Colombia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centro Servimed, Bucaramanga, Colombia","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034611468","display_name":"R. Guzm\u00e1n","orcid":"https://orcid.org/0000-0003-4163-6518","observed_orcids":["https://orcid.org/0000-0003-4163-6518"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. Guzman","raw_affiliation_strings":["Instituto de Enfermedades Autoinmunes Renato Guzm\u00e1n (IDEARG), Bogota, Colombia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto de Enfermedades Autoinmunes Renato Guzm\u00e1n (IDEARG), Bogota, Colombia","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040742321","display_name":"Jorge Hern\u00e1n Izquierdo","orcid":"https://orcid.org/0000-0002-3949-7638","observed_orcids":["https://orcid.org/0000-0002-3949-7638"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Izquierdo","raw_affiliation_strings":["Cl\u00ednica del Occidente, Cali, Colombia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cl\u00ednica del Occidente, Cali, Colombia","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"M. Abello","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Abello","raw_affiliation_strings":["Centro Integral de Reumatolog\u00eda Circaribe, Barranquilla, Colombia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centro Integral de Reumatolog\u00eda Circaribe, Barranquilla, Colombia","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105668328","display_name":"Patricia V\u00e9lez","orcid":"https://orcid.org/0009-0001-7502-1522","observed_orcids":["https://orcid.org/0009-0001-7502-1522"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P. Velez","raw_affiliation_strings":["Centro de Investigaci\u00f3n en Reumatolog\u00eda y Especialidades M\u00e9dicas (CIREEM), Bogota, Colombia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centro de Investigaci\u00f3n en Reumatolog\u00eda y Especialidades M\u00e9dicas (CIREEM), Bogota, Colombia","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110967972","display_name":"Dr Castillo","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Castillo","raw_affiliation_strings":["Cl\u00ednica del Occidente, Cali, Colombia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cl\u00ednica del Occidente, Cali, Colombia","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061786381","display_name":"Dar\u00edo Ponce de Le\u00f3n","orcid":"https://orcid.org/0000-0003-2250-6849","observed_orcids":["https://orcid.org/0000-0003-2250-6849"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. Ponce de Leon","raw_affiliation_strings":["Pfizer, Lima, Peru"],"raw_orcid":"https://orcid.org/0000-0003-2250-6849","affiliations":[{"raw_affiliation_string":"Pfizer, Lima, Peru","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103084500","display_name":"Tamara Luki\u0107","orcid":"https://orcid.org/0000-0001-8950-6304","observed_orcids":["https://orcid.org/0000-0001-8950-6304"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"T. Lukic","raw_affiliation_strings":["Pfizer Inc, New York, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, New York, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5014154029","display_name":"L. Amador","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"L. Amador","raw_affiliation_strings":["Pfizer, Bogota, Colombia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer, Bogota, Colombia","institution_ids":["https://openalex.org/I180857899"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5045599427"],"corresponding_institution_ids":["https://openalex.org/I180857899"],"apc_list":{"value":2300,"currency":"USD","value_usd":2300},"apc_paid":{"value":2300,"currency":"USD","value_usd":2300},"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"19","issue":"6","first_page":"319","last_page":"327"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11616","display_name":"Autoimmune and Inflammatory Disorders Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rheumatoid-arthritis","display_name":"rheumatoid arthritis","score":0.9909999966621399},{"id":"https://openalex.org/keywords/tofacitinib","display_name":"tofacitinib","score":1.0},{"id":"https://openalex.org/keywords/biological-dmards","display_name":"biologic DMARDs","score":0.878000020980835},{"id":"https://openalex.org/keywords/patient-reported-outcomes","display_name":"patient-reported outcomes","score":0.8899999856948853},{"id":"https://openalex.org/keywords/real-world-effectiveness","display_name":"real-world effectiveness","score":0.6919999718666077},{"id":"https://openalex.org/keywords/disease-activity","display_name":"disease activity","score":0.8029999732971191},{"id":"https://openalex.org/keywords/functional-status","display_name":"functional status","score":0.7860000133514404},{"id":"https://openalex.org/keywords/health-related-quality-of-life","display_name":"health-related quality of life","score":0.8899999856948853},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.984000027179718},{"id":"https://openalex.org/keywords/latin-america","display_name":"Latin America","score":0.6439999938011169},{"id":"https://openalex.org/keywords/colombia","display_name":"Colombia","score":0.531000018119812},{"id":"https://openalex.org/keywords/peru","display_name":"Peru","score":1.0},{"id":"https://openalex.org/keywords/jak-inhibitors","display_name":"JAK inhibitors","score":0.5759999752044678},{"id":"https://openalex.org/keywords/das28-esr","display_name":"DAS28-ESR","score":0.8500000238418579},{"id":"https://openalex.org/keywords/rapid3","display_name":"RAPID3","score":0.9369999766349792},{"id":"https://openalex.org/keywords/health-assessment-questionnaire-disability-index","display_name":"HAQ-DI","score":0.9739999771118164},{"id":"https://openalex.org/keywords/eq-5d-3l","display_name":"EQ-5D-3L","score":0.9049999713897705}],"concepts":[{"id":"https://openalex.org/C2778886723","wikidata":"https://www.wikidata.org/wiki/Q3530324","display_name":"Tofacitinib","level":3,"score":0.9488791823387146},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9370304346084595},{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.7864455580711365},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7282816171646118},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6156460642814636},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.5982129573822021},{"id":"https://openalex.org/C159110408","wikidata":"https://www.wikidata.org/wiki/Q121176","display_name":"Nursing","level":1,"score":0.0}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1016/j.reuma.2023.02.005","doi":"https://doi.org/10.1016/j.reuma.2023.02.005","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.reuma.2023.02.005","pdf_url":null,"source":{"id":"https://openalex.org/S2756385725","display_name":"Reumatolog\u00eda Cl\u00ednica","issn_l":"1699-258X","issn":["1699-258X","1885-1398"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","poland-40","russia-white-list-4"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Reumatolog\u00eda Cl\u00ednica","raw_type":"journal-article"},{"id":"doi:10.21203/rs.3.rs-828468/v2","doi":"https://doi.org/10.21203/rs.3.rs-828468/v2","is_oa":true,"landing_page_url":"https://doi.org/10.21203/rs.3.rs-828468/v2","pdf_url":null,"source":{"id":"https://openalex.org/S4306525896","display_name":"Research Square","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Research Square","raw_type":"posted-content"},{"id":"doi:10.21203/rs.3.rs-828468/v1","doi":"https://doi.org/10.21203/rs.3.rs-828468/v1","is_oa":true,"landing_page_url":"https://doi.org/10.21203/rs.3.rs-828468/v1","pdf_url":"https://www.researchsquare.com/article/rs-828468/latest.pdf","source":{"id":"https://openalex.org/S4306525896","display_name":"Research Square","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Research Square","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1016/j.reuma.2023.02.005","doi":"https://doi.org/10.1016/j.reuma.2023.02.005","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.reuma.2023.02.005","pdf_url":null,"source":{"id":"https://openalex.org/S2756385725","display_name":"Reumatolog\u00eda Cl\u00ednica","issn_l":"1699-258X","issn":["1699-258X","1885-1398"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","poland-40","russia-white-list-4"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Reumatolog\u00eda Cl\u00ednica","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4362575132.pdf","grobid_xml":"https://content.openalex.org/works/W4362575132.grobid-xml"},"referenced_works_count":30,"referenced_works":["https://openalex.org/W1558018690","https://openalex.org/W1761300068","https://openalex.org/W1976068756","https://openalex.org/W2014314115","https://openalex.org/W2014330392","https://openalex.org/W2025177742","https://openalex.org/W2035320881","https://openalex.org/W2046744512","https://openalex.org/W2056841944","https://openalex.org/W2069302785","https://openalex.org/W2070292873","https://openalex.org/W2094969739","https://openalex.org/W2128216805","https://openalex.org/W2128952811","https://openalex.org/W2137189844","https://openalex.org/W2142167031","https://openalex.org/W2149447280","https://openalex.org/W2153414586","https://openalex.org/W2164858045","https://openalex.org/W2343866616","https://openalex.org/W2411407713","https://openalex.org/W2607079988","https://openalex.org/W2917590838","https://openalex.org/W2920195602","https://openalex.org/W2926455583","https://openalex.org/W2979131994","https://openalex.org/W3047229059","https://openalex.org/W4230513158","https://openalex.org/W4235790631","https://openalex.org/W4255079226"],"related_works":["https://openalex.org/W3166744439","https://openalex.org/W2755144914","https://openalex.org/W1997061748","https://openalex.org/W2781665929","https://openalex.org/W2512318275","https://openalex.org/W2149447280","https://openalex.org/W4253107564","https://openalex.org/W3200598116","https://openalex.org/W2755298850","https://openalex.org/W4285098922"],"abstract_inverted_index":{"To":[0],"describe":[1],"efficacy,":[2],"safety,":[3],"and":[4,43,51,57,80,92,102,109,125,189,203,220,227,239],"patient-reported":[5],"outcomes":[6],"(PROs)":[7],"in":[8,32,49,164,222],"patients":[9,121,127],"with":[10,14,26,123,128],"rheumatoid":[11],"arthritis":[12],"(RA)":[13,261],"an":[15],"inadequate":[16],"response":[17],"to":[18],"conventional":[19],"synthetic":[20],"disease-modifying":[21],"antirheumatic":[22],"drugs":[23],"(csDMARDs)":[24],"treated":[25,122],"tofacitinib":[27,124,170,219,279,399,454,514],"or":[28],"biological":[29],"DMARDs":[30],"(bDMARDs)":[31],"real-life":[33],"conditions.":[34],"A":[35],"noninterventional":[36],"study":[37],"was":[38,138,147,159],"performed":[39],"between":[40,218],"March":[41],"2017":[42,297],"September":[44],"2019":[45,301],"at":[46,55,58,156],"13":[47,303],"sites":[48],"Colombia":[50,306],"Peru.":[52],"Outcomes":[53],"measured":[54],"baseline":[56,106,155,212],"the":[59,112,134,143,165],"6-month":[60],"follow-up":[61],"were":[62,98,107,130,208,213],"disease":[63,145],"activity":[64],"(RAPID3":[65],"[Routine":[66],"Assessment":[67,77,329,340],"of":[68,82,94,201,224,237,330],"Patients":[69,194,230,331],"Index":[70,332],"Data]":[71],"score),":[72,79],"functional":[73],"status":[74],"(HAQ-DI":[75],"[Health":[76],"Questionnaire]":[78],"quality":[81],"life":[83],"(EQ-5D-3L":[84],"[EuroQol":[85],"Questionnaire]).":[86],"The":[87,152],"Disease":[88],"Activity":[89],"Score-28":[90],"(DAS28-ESR)":[91,358],"frequency":[93],"adverse":[95],"events":[96],"(AEs)":[97],"also":[99],"reported.":[100,209],"Unadjusted":[101],"adjusted":[103,166],"differences":[104],"from":[105,119,154,195,211,231],"estimated":[108],"expressed":[110],"as":[111],"least":[113],"squares":[114],"mean":[115,136,144],"difference":[116],"(LSMD).":[117],"Data":[118,333],"100":[120,395],"70":[126,401],"bDMARDs":[129,172,221],"collected.":[131],"At":[132],"baseline,":[133],"patients\u2019":[135],"age":[137],"53.53":[139],"years":[140,149],"(SD":[141,150],"13.77),":[142],"duration":[146],"6.31":[148],"7.01).":[151],"change":[153],"month":[157],"6":[158,443],"not":[160,214],"statistically":[161,215],"significant":[162],"different":[163,217],"LSMD":[167],"[SD]":[168],"for":[169,173],"vs.":[171,177,182,187,192,455,462,469,476,483],"RAPID3":[174,225,459,519],"score":[175,180,185],"(\u22122.55[.30]":[176],"\u22122.52[.26]),":[178],"HAQ-DI":[179,466],"(\u2212.56[.07]":[181],"\u2212.50[.08]),":[183],"EQ-5D-3L":[184,473],"(.39[.04]":[186],".37[.04])":[188],"DAS28-ESR":[190,480],"(\u22122.37[.22]":[191],"\u22122.77[.20]).":[193],"both":[196,232],"groups":[197,233],"presented":[198,234],"similar":[199,235],"proportions":[200,236],"nonserious":[202,238],"serious":[204,240],"AEs.":[205,241],"No":[206],"deaths":[207],"Changes":[210],"significantly":[216],"terms":[223],"scores":[226],"secondary":[228],"outcomes.":[229],"NCT03073109.":[242,539],"Describir":[243],"la":[244,246,272,287,322,325,344,356,360,409,422,426,449],"eficacia,":[245],"seguridad":[247],"y":[248,298,307,314,343,359,372,380,400,421,479,498,515,520,537],"los":[249,253,267,316,377,413,456,516,522],"desenlaces":[250,310,523],"reportados":[251],"por":[252,387],"pacientes":[254,257,396,402,414,487,526],"(PRO)":[255],"en":[256,284,302,440,448,518,521],"con":[258,262,278,374,398,403,435],"artritis":[259],"reumatoide":[260],"una":[263],"respuesta":[264],"inadecuada":[265],"a":[266,315,376],"f\u00e1rmacos":[268],"antirreum\u00e1ticos":[269],"modificadores":[270],"de":[271,286,296,300,305,319,324,346,353,355,362,385,394,412,416,425,428,488,494,527,533],"enfermedad":[273,326,427],"sint\u00e9ticos":[274],"convencionales":[275],"(csFARME)":[276],"tratados":[277,397],"o":[280],"FARME":[281],"biol\u00f3gico":[282],"(bFARME)":[283],"condiciones":[285],"vida":[288,347],"real.":[289],"Estudio":[290],"no":[291,370,444,496,509,535],"intervencional":[292],"realizado":[293],"entre":[294,513],"marzo":[295],"septiembre":[299],"centros":[304],"Per\u00fa.":[308],"Los":[309,486,504,525],"evaluados":[311],"al":[312,437],"inicio":[313,406,508],"seis":[317],"meses":[318],"seguimiento":[320],"fueron":[321,510],"actividad":[323,354],"(puntaje":[327,338],"Routine":[328],"[RAPID3]),":[334],"el":[335,441,507],"estado":[336],"funcional":[337],"Health":[339],"Questionnaire":[341,349],"[HAQ-DI])":[342],"calidad":[345],"(EuroQol":[348],"[EQ-5D-3L]).":[350],"El":[351,433],"puntaje":[352],"enfermedad-28":[357],"frecuencia":[361],"eventos":[363],"adversos":[364],"(EA).":[365],"Se":[366,391],"estimaron":[367],"las":[368],"diferencias":[369],"ajustadas":[371,373],"respecto":[375,436],"valores":[378],"basales":[379],"se":[381],"expresaron":[382],"como":[383],"diferencia":[384],"medias":[386],"m\u00ednimos":[388],"cuadrados":[389],"(LMD).":[390],"recolect\u00f3":[392],"informaci\u00f3n":[393],"bFARME.":[404],"Al":[405],"del":[407],"estudio,":[408],"edad":[410],"media":[411,424],"era":[415],"53,53":[417],"a\u00f1os":[418,430],"(DE":[419,431],"13,77)":[420],"duraci\u00f3n":[423],"6,31":[429],"7,01).":[432],"cambio":[434],"valor":[438],"basal":[439],"mes":[442],"fue":[445,502],"estad\u00edsticamente":[446,511],"significativo":[447],"LMD":[450],"ajustada":[451],"(SE)":[452],"para":[453,458],"bFARME":[457,517],"(\u22122,55":[460],"[0,30]":[461],"\u22122,52":[463],"[0,26]),":[464],"puntuaci\u00f3n":[465,472],"(\u22120,56":[467],"[0,07]":[468],"\u22120,50":[470],"[0,08]),":[471],"(0,39":[474],"[0,04]":[475],"0,37":[477],"[0,04])":[478],"(\u22122,37":[481],"[0,22]":[482],"\u22122,77":[484],"[0,20]).":[485],"ambos":[489,528],"grupos":[490,529],"presentaron":[491,530],"proporciones":[492,531],"similares":[493,532],"EA":[495,534],"graves":[497,536],"graves.":[499,538],"Ninguna":[500],"muerte":[501],"reportada.":[503],"cambios":[505],"desde":[506],"significativos":[512],"secundarios.":[524]},"counts_by_year":[],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2023-04-06T00:00:00"}